Acute Hypertension Therapeutics
1. Cleviprex patent expiration
Treatment: Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable
CLEVIPREX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5856346 | CHIESI | Short-acting dihydropyridines |
Jan, 2021
(5 years ago) | |
| US5739152 | CHIESI | Pharmaceutical emulsion |
Apr, 2015
(10 years ago) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2013 |
Drugs and Companies using CLEVIDIPINE ingredient
NCE-1 date: 01 August, 2012
Market Authorisation Date: 01 August, 2008
Dosage: EMULSION
How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage
CLEVIPREX family patents
